{"url_path":"/sec/clb/8-k/2026-05-13/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1958086/0001193125-26-221857-index.html","accession_number":"0001193125-26-221857","cik":"0001958086","ticker":"CLB","issuer_name":"Core Laboratories Inc. /DE/","edgar_url":"https://www.sec.gov/Archives/edgar/data/1958086/0001193125-26-221857-index.html","primary_entity_key":"0001958086","primary_entity_name":"Core Laboratories Inc. /DE/"},"word_count":416,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nCore Laboratories Inc. (the “Company”) held its Annual Meeting of Shareholders (the “Annual Meeting”) on May 12, 2026 in Houston, Texas. At the Annual Meeting, the Company’s shareholders were asked to vote on the following proposals: (1) to re-elect two current Class I Directors to serve under the terms and conditions described within the Company’s proxy statement until its annual meeting in 2029 and until their successors shall have been duly elected and qualified; (2) to ratify the appointment of KPMG LLP as the Company’s independent registered public accountant for the year ending December 31, 2026; and (3) to approve, on an advisory basis, the compensation philosophy, policies and procedures described in the section of the Company’s proxy statement entitled “Compensation Discussion and Analysis” and the compensation of the Company’s named executive officers as disclosed pursuant to the U.S. Securities and Exchange Commission’s compensation disclosure rules, including the compensation tables.\n\nGiven that more than 50% of the issued share capital was present and represented at the Annual Meeting either in person or by proxy, proposal 1 could be approved by the affirmative vote of a plurality of votes cast, and proposals 2 and 3 could be approved by the affirmative vote of holders of a majority of shares present in person or represented by proxy and entitled to vote. All items were approved, and the certified results of the matters voted upon at the Annual Meeting are as follows:\n\nProposal 1 – Election of Class I Directors: The election of each Class I director was approved as follows:\n\nNominee\n\n \n\nFor\n\n \n\nWithheld\n\n \n\nBroker Non-Votes\n\nHarvey Klingensmith\n\n \n\n35,880,017\n\n \n\n3,756,385\n\n \n\n2,077,874\n\nCurtis Anastasio\n\n \n\n39,271,486\n\n \n\n364,916\n\n \n\n2,077,874\n\nProposal 2 – Appointment of KPMG as Independent Registered Public Accountant: The ratification of the appointment of KPMG as the Company’s independent registered public accountant for the fiscal year ending December 31, 2026 was approved as follows:\n\nFor\n\n \n\nAgainst\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n41,220,974\n\n \n\n484,159\n\n \n\n9,143\n\n \n\n—\n\nProposal 3 – Approving the Compensation of the Company’s Named Executive Officers: An advisory vote on the compensation of the Company’s named executive officers was approved as follows:\n\nFor\n\n \n\nAgainst\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n38,265,683\n\n \n\n1,263,224\n\n \n\n107,495\n\n \n\n2,077,874\n\n \n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nCore Laboratories Inc.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDated: May 13, 2026\n\n \n\nBy\n\n \n\n/s/ Christopher S. Hill\n\n \n\n \n\n \n\n \n\n \n\n \n\nChristopher S. Hill\n\n \n\n \n\n \n\n \n\n \n\n \n\nChief Financial Officer"}